STOCK TITAN
  1. Home
  2. Sec-filings
  3. IOVA
  4. [Form 4] IOVANCE BIOTHERAPEUTICS, INC. Insider Trading Activity

Iovance COO has 8,789 RSUs vest into shares

COO Igor Bilinsky had RSUs vest into common stock, with a portion of shares withheld to cover tax obligations.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Operating Officer Igor Bilinsky had 8,789 Restricted Stock Units (RSUs) vest on September 1, 2026, resulting in the issuance of 8,789 shares of common stock. Of these, 4,472 shares of common stock were withheld at $8.28 per share to satisfy mandatory tax withholding, which the company states was not an open market sale. Following the transaction, 17,580 RSUs from the March 1, 2024 grant remain outstanding and will vest in equal quarterly installments; this aggregate RSU figure does not include any other RSUs he holds.

Positive

  • None.

Negative

  • None.
Insider BILINSKY IGOR
Role Chief Operating Officer
Type Security Shares Price Value
Exercise Restricted Stock Units F4, F5, F6 8,789 $0.00 $0.00
Exercise Common Stock F1 8,789 $0.00 $0.00
Tax Withholding Common Stock F2, F3 4,472 $8.28 $37K
Holdings After Transaction: Restricted Stock Units — 17,580 contracts (Direct); Common Stock — 138,237 shares (Direct)
Footnotes (6)
  1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
  2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
  3. F3. Represents common stock remaining after deducting the common stock withheld for taxes.
  4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  5. F5. The remaining RSUs will vest in equal quarterly installments.
  6. F6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
RSUs vested 8,789 units RSUs vested for COO on September 1, 2026
Common shares issued from RSUs 8,789 shares Shares of common stock received upon RSU vesting
Shares withheld for taxes 4,472 shares Common stock withheld to satisfy mandatory tax withholding
Tax withholding price $8.28 per share Value used for shares withheld to cover tax liability
RSUs remaining from March 1, 2024 grant 17,580 units Unvested RSUs that will vest in equal quarterly installments
Restricted Stock Units financial
"Represents such shares underlying the restricted stock units ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
mandatory tax withholding financial
"to satisfy the mandatory tax withholding requirements upon vesting"
contingent right financial
"Each RSU represents a contingent right to receive one share"
equal quarterly installments financial
"The remaining RSUs will vest in equal quarterly installments"

FAQ

What insider transaction did IOVA report for COO Igor Bilinsky?
IOVANCE BIOTHERAPEUTICS reported that COO Igor Bilinsky had 8,789 RSUs vest on September 1, 2026, converting into the same number of common shares, with a portion of those shares withheld to cover tax obligations.

How many IOVA RSUs vested for the COO and into how many shares?
On September 1, 2026, 8,789 RSUs held by the COO vested, and each RSU represented a contingent right to receive one share, resulting in 8,789 shares of IOVA common stock being issued.

How many IOVA shares were withheld for taxes and at what price?
To satisfy mandatory tax withholding upon RSU vesting, 4,472 shares of IOVANCE common stock were withheld at a price of $8.28 per share. The company notes this was not an open market sale of securities.

How many IOVA RSUs remain outstanding from the March 1, 2024 grant?
After this vesting event, 17,580 RSUs from the March 1, 2024 grant remain outstanding for the COO, and these RSUs are scheduled to vest in equal quarterly installments.

Were the reported IOVA insider transactions under a Rule 10b5-1 plan?
No. The filing indicates that no Rule 10b5-1 trading plan is affirmed for these transactions, and there is no footnote stating that they were executed pursuant to such a plan.

Did the IOVA COO sell any shares in the open market in this Form 4?
No. The filing states that the 4,472 shares of common stock were withheld by the issuer to satisfy tax withholding requirements, and explicitly clarifies this is not an open market sale of securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BILINSKY IGOR
(Last)(First)(Middle)
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, SUITE 100
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)09/01/2026M8,789A$0142,709D
Common Stock(2)09/01/2026F4,472D$8.28138,237(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(4)09/01/2026M8,789 (5) (5)Common stock8,789$0.0017,580(6)D
Explanation of Responses:
1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. Represents common stock remaining after deducting the common stock withheld for taxes.
4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. The remaining RSUs will vest in equal quarterly installments.
6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
/s/ Igor Bilinsky09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR